About: Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 December 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2007 (uk) im März 2007 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 11 December 2006 (en) 2006 թվականի դեկտեմբերի 11-ին հրատարակված գիտական հոդված (hy) artículu científicu espublizáu n'avientu de 2006 (ast)
publication date	wds:Q59616816-E44D0F88-8707-44F4-92D7-7FD91420571C
publication date	2006-12-11 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q59616816-667C5AB9-B395-48F5-BE2F-B71E952CC5E1
language of work or name	English
author name string	wds:Q59616816-03B40F44-2DF0-4EE0-AF7F-4780ACEEA384 wds:Q59616816-20BF9112-F5B9-4AEA-A7B6-CE69636F1B3F wds:Q59616816-395E8845-12E1-421A-8871-9A20E94BE74F wds:Q59616816-451B19A9-D032-46D7-B7F7-450212ABB0F0 wds:Q59616816-491C9492-EB9D-4A46-923E-AF8547194D82 wds:Q59616816-6084C389-74BF-401A-ABE4-7941CF2A7B90 wds:Q59616816-769693D3-C589-461F-91BA-09BAA72D8467 wds:Q59616816-95556603-2569-498A-9D9F-0F344A9BB1A3 wds:Q59616816-9F490E98-577A-41B5-B466-B328732E777C wds:Q59616816-AE07065C-1968-4F1E-A24B-E6C86B5A6777 wds:Q59616816-C7A80ED6-E3BC-40D0-8C79-80DC1715E903 wds:Q59616816-CD71B928-AE02-49B9-BD07-BE1AE259D50B
author name string	Marianne Schmid Austrian Breast and Colorectal Cancer Study Group Raimund Jakesz Brigitte Mlineritsch Christian Menzel Arik Galid Hubert Hausmaninger Martina Mittlboeck Helmut Kaessmann Stephan Grampp Gero Luschin-Ebengreuth Jutta Claudia Piswanger-Soelkner
rdfs:label	Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group (en) Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group (nl)
skos:prefLabel	Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group (en) Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group (nl)
name	Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group (en) Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group (nl)
author	wds:Q59616816-D3AC9158-466C-4BFA-BF2D-EC6BD9F96DD4
author	Michael Gnant
title	wds:Q59616816-55C636CD-2CD8-4985-92E3-258F290B6CB8
title	Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group (en)
page(s)	wds:Q59616816-4DF9218B-AB30-48D0-8026-97B36F88D663
page(s)	820-828
instance of	wds:Q59616816-EC780D95-B4C2-4705-862A-3B5AF5C8874C
instance of	scholarly article
main subject	wds:Q59616816-2C154971-2E6A-444E-B3B3-24E2BFB3697E wds:Q59616816-4A688D57-EA2E-4A4D-AF7A-8C7971621845 wds:Q59616816-9F2A3C93-D45E-47C6-A1B9-F409043F480D wds:Q59616816-B13D950A-6408-4E61-8045-EE3D4A530F54
main subject	wd:Q218507 breast cancer colorectal cancer colorectal carcinoma
PubMed ID	wds:Q59616816-C0C39610-A458-4AFB-8D09-6AEC82DE34BC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17159195
PubMed ID	17159195
published in	wds:Q59616816-784024E9-D3B0-425E-9987-1FEBA0F830CE
published in	Journal of Clinical Oncology
issue	wds:Q59616816-30C7FADD-D5BC-4898-912E-DB9A7400720C
volume	wds:Q59616816-81A4F6C8-18C4-4C78-870B-DAF7138F04FF
issue	7
volume	25
DOI	wds:Q59616816-C100E563-137A-4C90-92A9-F24ACA946F91
DOI	http://dx.doi.org/10.1200/JCO.2005.02.7102
DOI	10.1200/JCO.2005.02.7102
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59616816
is cites work of	Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab Cancer-associated bone disease Risks and benefits of bisphosphonates The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer Zoledronic acid use in cancer patients: more than just supportive care? Aromatase inhibitor-associated bone loss: clinical considerations Breast cancer in young women and its impact on reproductive function Metastasis and bone loss: advancing treatment and prevention. Bisphosphonates: mechanism of action and role in clinical practice Bone loss in patients with breast or prostate cancer Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer Symptom management in premenopausal patients with breast cancer The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer Increased fracture rate in women with breast cancer: a review of the hidden risk Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Zoledronic acid : a review of its use in the management of bone metastases of malignancy Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer Osteoporosis in young adults: pathophysiology, diagnosis, and management. Medication-induced osteoporosis Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software